VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | NEO-Nal-IRI: liposomal irinotecan + 5-FU & oxaliplatin in panceratic cancer

Brian H. Ramnaraign, MD, University of Florida College of Medicine, Gainesville, FL, outlines the ongoing NEO-Nal-IRI study, a Phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in the preoperative treatment of pancreatic adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter